LYPLA1

Across TCGA pan-cancer cohorts, LYPLA1 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of LYPLA1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where LYPLA1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LYPLA1 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

HNSC, BLCA, and UCEC are the cancer types where LYPLA1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYPLA1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.526	<.001	10	view →
BLCA	Male	III,IV	+1.558	<.001	9	view →
UCEC	All	III,IV	+1.258	<.001	8	view →
STAD	All	II,III,IV	+0.862	<.001	8	view →
KIRC	Male	All	−0.532	<.001	8	view →
LIHC	Male	All	+1.082	<.001	7	view →
LUAD	Male	II,III,IV	+1.179	<.001	6	view →
BRCA	All	II,III,IV	+1.052	<.001	6	view →
LUSC	All	All	+0.766	<.001	6	view →
THCA	Female	All	−0.388	<.001	6	view →
COAD	All	II,III,IV	+0.691	<.001	5	view →
READ	Male	All	+0.910	.007	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

LYPLA1–HNSC

Open the HNSC breakdown →